ARON 3D_Transparent

Renal Cell Carcinoma

Cabo nivo vs pembro axi 1

Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients withmetastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)

Santoni M
Cancer Immunol Immunother.
2025
Obesity ARON 1

Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)

Santoni M
et al. Clin Genitourin Cancer
2023
0 3 1

First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study

Roviello
Roviello et al. Cancer Immunol Immunother
2025
MvtEc 1dQ1yGiYkyTNFLwQ

Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study. 

Santoni M, et al.
Target Oncol.
2023
1733740143737

Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? 

Santoni M, et al.
Eur Urol Oncol.
2024
DBuV105KSlW5ffDBdIDZ0A

Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations

Porta C, et al.
Minerva Urol Nephrol.
2023

Do you want to join us ?

Join us today
ARON 3D_Transparent
Youtube Linkedin

Coordinated and designed by Atteggiamento Digitale .

Legal and Privacy.